Tracey Sacco Sells 6,500 Shares of Scholar Rock Holding Co. (NASDAQ:SRRK) Stock

Scholar Rock Holding Co. (NASDAQ:SRRK) insider Tracey Sacco sold 6,500 shares of Scholar Rock stock in a transaction on Monday, March 24th. The stock was sold at an average price of $33.08, for a total value of $215,020.00. Following the completion of the sale, the insider now directly owns 71,750 shares of the company’s stock, valued at approximately $2,373,490. The trade was a 8.31 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link.

Scholar Rock Stock Down 3.4 %

Scholar Rock stock opened at $32.16 on Thursday. The stock has a market cap of $3.04 billion, a PE ratio of -13.69 and a beta of 0.59. The company has a debt-to-equity ratio of 0.63, a quick ratio of 3.88 and a current ratio of 3.88. The stock has a fifty day moving average of $38.15 and a 200 day moving average of $32.72. Scholar Rock Holding Co. has a one year low of $6.76 and a one year high of $46.98.

Analyst Ratings Changes

Separately, Wedbush reissued an “outperform” rating and issued a $50.00 target price on shares of Scholar Rock in a research report on Tuesday. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $40.86.

Hedge Funds Weigh In On Scholar Rock

Several institutional investors have recently made changes to their positions in SRRK. GAMMA Investing LLC raised its position in Scholar Rock by 51.8% in the fourth quarter. GAMMA Investing LLC now owns 788 shares of the company’s stock worth $34,000 after acquiring an additional 269 shares during the period. JPMorgan Chase & Co. raised its holdings in Scholar Rock by 1.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 38,726 shares of the company’s stock worth $310,000 after purchasing an additional 379 shares during the period. Amalgamated Bank lifted its position in Scholar Rock by 30.6% during the fourth quarter. Amalgamated Bank now owns 2,643 shares of the company’s stock valued at $114,000 after purchasing an additional 620 shares in the last quarter. Global Retirement Partners LLC increased its position in Scholar Rock by 584.7% in the fourth quarter. Global Retirement Partners LLC now owns 897 shares of the company’s stock worth $39,000 after buying an additional 766 shares in the last quarter. Finally, Nisa Investment Advisors LLC lifted its position in shares of Scholar Rock by 1,321.8% during the 4th quarter. Nisa Investment Advisors LLC now owns 1,109 shares of the company’s stock valued at $48,000 after buying an additional 1,031 shares in the last quarter. Institutional investors own 91.08% of the company’s stock.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.